Table 2.
Clinical and pathologic features by racial/age group for patients receiving NACT
| Young Black | Young White | Older Black | Older White | p-value† | |
|---|---|---|---|---|---|
| N = 59 | N = 102 | N = 120 | N = 116 | ||
| Age at diagnosis | 34.0 (4.9) | 34.9 (3.7) | 65.4 (7.7) | 63.1 (5.7) | NR |
| Tumor size (mm) | 44.6 (27.7) | 49.7 (98.1) | 38.4 (25.5) | 37.0 (27.7) | 0.31* |
| Lymph node status | 0.017 | ||||
| 0 | 23 (46.0%) | 54 (63.5%) | 74 (69.2%) | 60 (59.4%) | |
| 1–3 | 20 (40.0%) | 16 (18.8%) | 20 (18.7%) | 20 (19.8%) | |
| 4–9 | 2 (4.0%) | 12 (14.1%) | 10 (9.3%) | 15 (14.9%) | |
| 10 + | 5 (10.0%) | 3 (3.5%) | 3 (2.8%) | 6 (5.9%) | |
| Receptor status | 0.002 | ||||
| HR + /HER2− | 22 (37.9%) | 33 (32.7%) | 24 (20.5%) | 36 (31.9%) | |
| HR + /HER2 + | 15 (25.9%) | 24 (23.8%) | 22 (18.8%) | 28 (24.8%) | |
| HR−/HER2 + | 5 (8.6%) | 6 (5.9%) | 11 (9.4%) | 20 (17.7%) | |
| Triple negative | 16 (27.6%) | 38 (37.6%) | 60 (51.3%) | 29 (25.7%) | |
| Stage | 0.22 | ||||
| 1 | 5 (9.5%) | 22 (21.6%) | 17 (14.2%) | 20 (17.2%) | |
| 2 | 32 (54.2%) | 58 (56.9%) | 72 (60.0%) | 64 (55.2%) | |
| 3 | 22 (37.3%) | 22 (21.6%) | 31 (25.8%) | 32 (27.6%) | |
| Tumor grade | 0.25 | ||||
| 1 | 2 (4%) | 1 (1%) | 1 (1%) | 3 (3%) | |
| 2 | 13 (23%) | 19 (19%) | 15 (13%) | 27 (25%) | |
| 3 | 42 (74%) | 78 (80%) | 98 (86%) | 80 (73%) |
Data are presented as mean (SD) for continuous measures, and n(%) for categorical measures
HR hormone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, NR not relevant
†Chi-squared test, except *ANOVA